The main objective of this WP is 1) to identify a method to assess the potential medical, social, economic and ethical impact of a risk stratification for patients with endocrine hypertension and 2) to test it with the trial run in WP4

The specific objectives of this WP are to:

  1. To systematic review of the literature, identification of stakeholders, tools and methods used in the assessment of stratified medicine
  2. To identify the knowledge gap with reference to the EUNetHTA core models
  3. To list the markers that have shown good potential for stratification (HR >3.5) and can be used in clinical studies
  4. To provide a roadmap for validation studies
  5. To provide an economic evaluation of the stratified approach
10_uob.png11_rumc.png12_uom.png13_it.png1_inserm.png2_aphp.png3_lmu.png4_hmgu.png5_tud.png6_unito.png7_unipd.png8_uod.png9_ugla.png

People

Scientific Coordinator: Dr Maria -Christina Zennaro, Head of INSERM U970 team 14: Genetic mechanisms of aldosterone-related disorders. maria-christina.zennaro@inserm.fr

Project Manager (INSERM-Transfert): Catherine Clusel catherine.clusel@inserm-transfert.fr

Project Manager (INSERM-Transfert): Kristina Fiedler kristina.fiedler@inserm-transfert.fr

More contact details here

Places

Paris Cardiovascular Research Center (PARCC), European Georges Pompidou Hospital, 56 rue Leblanc, 75015 Paris, France

INSERM-Transfert, Paris Biopark, 7 rue Watt, 75013 Paris, France

Maps

European Georges Pompidou Hospital


View Larger Map

INSERM-Transfert


View Larger Map

Go to top
JSN Blank template designed by JoomlaShine.com